Nektar Therapeutics
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 05/05/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Nektar Therapeutics |
| Court: | Court: Northern District of California |
| Case Number: | Case Number: 5:26cv01951 |
| Class Period: | Class Period: 02/26/2025 - 12/15/2025 |
| Ticker: | Ticker: NKTR |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ:NKTR) securities during the period of February 26, 2025 through December 15, 2025, inclusive (“the Class Period”).
The lawsuit alleges that (i) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (iii) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On December 16, 2025, Nektar issued a press release "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin[.]" The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate. On this news, the price of Nektar shares declined by $4.14 per share, or approximately 7.8%, from $53.30 per share on December 15, 2025 to close at $49.16 on December 16, 2025.